Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Immunotherapy, Surgery.

University Hospital Leuven, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Leuven
Treatments:Immunotherapy, SurgeryHospital:University Hospital Leuven
Drugs:Journal:Link
Date:May 2008

Description:

Patients: This study involved 56 patients with relapsed glioblastoma multiforme. The median age was 45, ranging from 7-77 years of age. There were 36 males and 20 females in the study.

Treatment: After surgery, patients were treated with an immunotherapy. The immunotherapy was a vaccine made up of a type of cell from the body (dendritic cell), designed to enable the immune system to better kill the tumor cells.

Toxicity: Grade 2 hematological toxicity was reported in two patients. Grade 4 neurotoxicity (stupor) was reported in one patient. Other toxicities included flu-like symptoms, dizziness, pneumonia, myalgia, vomiting, and an increase in epileptic seizures.

Results: The median overall survival was 9.6 months. The overall survival in patients who were 35 years old or younger was 15.4 months, and 7.5 months for those older than 35.

Correspondence: Dr. Steven De Vleeschouwer



Back